Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Feb 10, 2026 · Filed Feb 11, 2026
F5, Inc.'s Chief Product Mkting Officer sold $281K of F5, Inc. shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$280,660
Shares × reported transaction price
14 days after results of Jan 27, 2026, 77 days before results of Apr 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $282.38 on Feb 10, 2026, 26% above its 52-week low and 18% below its high, after a 7% rise over the previous 30 trading days
52-week range $223.99 (Nov 19, 2025) to $343.17 (Oct 14, 2025), 49% of the way up, from 251 adjusted closes. 30 trading days earlier: $263.14 on Dec 26, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +6.5% | +0.5% | +6.1% |
| 30 days | +8.3% | -1.8% | +10.1% |
| 90 days | +36.4% | +9.0% | +27.4% |
| 180 days | +58.0% | +13.1% | +44.9% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Compensation award — excluded from discretionary-purchase analysis.
Derivative exercise or conversion — not an open-market buy.
